1. Home
  2. STKS vs BYSI Comparison

STKS vs BYSI Comparison

Compare STKS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

HOLD

Current Price

$1.85

Market Cap

58.4M

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

HOLD

Current Price

$1.67

Market Cap

58.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKS
BYSI
Founded
2004
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.4M
58.4M
IPO Year
2011
2016

Fundamental Metrics

Financial Performance
Metric
STKS
BYSI
Price
$1.85
$1.67
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.70
N/A
AVG Volume (30 Days)
20.1K
19.4K
Earning Date
05-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$805,722,000.00
N/A
Revenue This Year
$7.47
N/A
Revenue Next Year
$8.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.66
N/A
52 Week Low
$1.65
$1.18
52 Week High
$4.67
$2.44

Technical Indicators

Market Signals
Indicator
STKS
BYSI
Relative Strength Index (RSI) 47.34 47.43
Support Level $1.70 $1.55
Resistance Level $2.06 $1.83
Average True Range (ATR) 0.12 0.11
MACD -0.00 -0.00
Stochastic Oscillator 20.95 26.32

Price Performance

Historical Comparison
STKS
BYSI

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: